Cerebrovascular reserve testing via transcranial Doppler ultrasound useful in identifying asymptomatic patients with carotid artery stenosis at risk for stroke.
Cerebrovascular reserve (CVR) testing can help identify asymptomatic patients with carotid artery stenosis who are most likely to benefit from revascularization, according to an article published online in the journal Radiology.
Researchers from Weill Cornell Medical College in New York, NY, sought to project and compare the lifetime health benefits, healthcare costs and incremental cost-effectiveness of stroke prevention strategies among patients who had carotid artery stenosis but were also asymptomatic.
For the study, the researchers used transcranial Doppler (TCD) sonography and constructed a mathematical model that allowed them to make hypothetical comparisons among three different approaches: CVR testing, immediate revascularization with carotid endarterectomy and medical therapy-based management with subsequent revascularization only for patients whose stenosis worsened.
“A decision analytic model was developed to project lifetime quality-adjusted life years (QALYs) and costs for asymptomatic patients with carotid stenosis with 70 percent to 89 percent carotid luminal narrowing at presentation,” the authors wrote.
The results showed that the medical therapy-based strategy was associated with the lowest lifetime costs and the fewest revascularizations. However, this strategy also resulted in the lowest life expectancy and lifetime quality-adjusted years.
“The study results show that imaging can be a cost-effective tool to stratify patients by risk of stroke and help sort patients into invasive, expensive interventions and less invasive options,” co-author Ankur Pandya, PhD, assistant professor of healthcare policy and research and public health in radiology at Weill Cornell Medical College, said in a release. “There are complications and costs associated with these revascularization procedures, and they are often done without knowing if the risks and costs are worth the benefits.”
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.